Subscribe to our newsletter for the latest leadership tips, exclusive interviews, and expert advice from top CEOs. Simply enter your email below and stay ahead of the curve!.
Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.